Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy

Journal of International Medical Research

Volumn 41, Issue 4, 2013, Pages 1150-1159

  Hammoudeh, Mohammed ^a   Zack, Debra J ^b   Li, Wenzhi ^c   Stewart, V Michelle ^d   Koenig, Andrew S ^d  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b AMGEN INC   (United States)

^c PharmaNet i3   (United States)

^d PFIZER INC   (United States)

Author keywords

Ankylosing spondylitis; back pain; C reactive protein; etanercept; fatigue; sulfasalazine

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PROTEIN BLOOD LEVEL; TREATMENT DURATION; VISUAL ANALOG SCALE;

EID: 84887341183     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513488501     Document Type: Article

References (29)

1. Jones SD,Koh WH,Steiner A,et al.Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors.J Rheumatol. 1996;23:487-490.
2. Bodur H,Ataman S,Rezvani A,et al.Quality of life and related variables in patients with ankylosing spondylitis.Qual Life Res. 2011;20:543-549.
3. Dagfinrud H,Vollestad NK,Loge JH,et al.Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures.Arthritis Rheum. 2005;53:5-11.
4. Aissaoui N,Rostom S,Hakkou J,et al.Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance.Rheumatol Int. 2012;32:2117-2124.
5. Glintborg B,Østergaard M,Krogh NS,et al.Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.Ann Rheum Dis. 2010;69:2002-2008.
6. Lord PA,Farragher TM,Lunt M,et al.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford). 2010;49:563-570.
7. Arends S,Brouwer E,van der Veer E,et al.Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.Arthritis Res Ther. 2011;13:R94-R94.
8. van der Heijde D,Lie E,Kvien TK,et al.ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.Ann Rheum Dis. 2009;68:1811-1818.
9. Vastesaeger N,van der Heijde D,Inman RD,et al.Predicting the outcome of ankylosing spondylitis therapy.Ann Rheum Dis. 2011;70:973-981.
10. Davis JC Jr,Van der Heijde DM,Dougados M,et al.Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.J Rheumatol. 2005;32:1751-1754.
11. Rudwaleit M,Listing J,Brandt J,et al.Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.Ann Rheum Dis. 2004;63:665-670.
12. Hultgren S,Broman JE,Gudbjörnsson B,et al.Sleep disturbances in outpatients with ankylosing spondylitisa questionnaire study with gender implications.Scand J Rheumatol. 2000;29:365-369.
13. van Tubergen A,Coenen J,Landewé R,et al.Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis.Arthritis Rheum. 2002;47:8-16.
14. Missaoui B,Revel M.Fatigue in ankylosing spondylitis [in French, English abstract].Ann Readapt Med Phys. 2006;49:305-308, 389-391.
15. Günaydin R,Göksel Karatepe A,Ceşmeli N,et al.Fatigue in patients with ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep disturbance.Clin Rheumatol. 2009;28:1045-1051.
16. Dernis-Labous E,Messow M,Dougados M.Assessment of fatigue in the management of patients with ankylosing spondylitis.Rheumatology (Oxford). 2003;42:1523-1528.
17. Braun J,van den Berg R,Baraliakos X,et al.2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.Ann Rheum Dis. 2011;70:896-904.
18. Davis JC Jr,Van Der Heijde D,Braun J,et al.Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.Arthritis Rheum. 2003;48:3230-3236.
19. Brandt J,Khariouzov A,Listing J,et al.Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.Arthritis Rheum. 2003;48:1667-1675.
20. Calin A,Dijkmans BA,Emery P,et al.Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.Ann Rheum Dis. 2004;63:1594-1600.
21. Davis JC Jr,van der Heijde DM,Braun J,et al.Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.Ann Rheum Dis. 2008;67:346-352.
22. Dijkmans B,Emery P,Hakala M,et al.Etanercept in the longterm treatment of patients with ankylosing spondylitis.J Rheumatol. 2009;36:1256-1264.
23. van der Heijde D,Da Silva JC,Dougados M,et al.Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.Ann Rheum Dis. 2006;65:1572-1577.
24. Braun J,van der Horst-Bruinsma IE,Huang F,et al.Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.Arthritis Rheum. 2011;63:1543-1551.
25. van der Linden S,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.Arthritis Rheum. 1984;27:361-368.
26. Garrett S,Jenkinson T,Kennedy LG,et al.A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.J Rheumatol. 1994;21:2286-2291.
27. Lacaille D,White MA,Backman CL,et al.Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective.Arthritis Rheum. 2007;57:1269-1279.
28. Ram S,Seirawan H,Kumar SK,et al.Prevalence and impact of sleep disorders and sleep habits in the United States.Sleep Breath. 2010;14:63-70.
29. Li W,Stewart M,Koenig AS.Change in back pain over time as a function of C-reactive protein across studies of ankylosing spondylitis. American College of Rheumatology/ARHP Annual Scientific Meeting [abstract/poster].Arthritis Rheum. 2011;63:S504-S504.